Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
139.94B
Market cap139.94B
Price-Earnings ratio
27.39
Price-Earnings ratio27.39
Dividend yield
Dividend yield
Average volume
1.50M
Average volume1.50M
High today
$546.17
High today$546.17
Low today
$501.89
Low today$501.89
Open price
$540.60
Open price$540.60
Volume
2.68M
Volume2.68M
52 Week high
$546.17
52 Week high$546.17
52 Week low
$362.50
52 Week low$362.50

Stock Snapshot

The current Vertex Pharmaceuticals(VRTX) stock price is $524.79, with a market capitalization of 139.94B. The stock trades at a price-to-earnings (P/E) ratio of 27.39.

During the trading session on 2026-08-11, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $546.17 and a low of $501.89. At a current price of $524.79, the stock is +4.6% higher than the low and still -3.9% under the high.

Trading activity shows a volume of 2.68M, compared to an average daily volume of 1.5M.

The stock's 52-week range extends from a low of $362.50 to a high of $546.17.

The stock's 52-week range extends from a low of $362.50 to a high of $546.17.

VRTX News

The Motley Fool 5h
Vertex Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Dr. Reshma Kewalramani Chief Oper...

Vertex Q2 2026 Earnings Call Transcript
Investing.com 12h
Wolfe Research raises Vertex stock price target on CF franchise value - Investing.com

...

Wolfe Research raises Vertex stock price target on CF franchise value - Investing.com
TipRanks 14h
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy rating on the shares after competitor Sionna Therapeutics...

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More VRTX News

TipRanks 14h
Vertex Stock Soars 7% as Rival Sionna Crashes 92% on Failed Drug Trial

Shares of American biotech company Vertex Pharmaceuticals (VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics (SION) reported the failure o...

Investor's Business Daily 17h
Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Technology Why Vertex Pharma Popped, As A Key Rival Plummeted 90% Licensing Vertex stock surged Monday after its competitor, Sionna Therapeutics (SION), missed...

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%
Simply Wall St 1d
Vertex Pharmaceuticals On Guidance Upgrade And Pipeline Growth Narrative】【。

Advertisement Earnings guidance change and new partnership set the context for Vertex Pharmaceuticals stock Vertex Pharmaceuticals (VRTX) recently reported se...

Vertex Pharmaceuticals On Guidance Upgrade And Pipeline Growth Narrative】【。
Simply Wall St 3d
Vertex Stock Looks Reasonably Priced As Its 155% Run Continues

Vertex Pharmaceuticals stock has delivered a strong 155.4% return over the past 5 years, yet the current valuation picture is mixed, with the Discounted Cash Fl...

Vertex Stock Looks Reasonably Priced As Its 155% Run Continues
Nasdaq 3d
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Key Points Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and...

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
Simply Wall St 6d
Novo Nordisk Stock Shock Has Investors Rethinking Obesity Drug Exposure

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reactio...

Novo Nordisk Stock Shock Has Investors Rethinking Obesity Drug Exposure
TipRanks 6d
Vertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment

Vertex Pharmaceuticals Inc. ((VRTX)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investin...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.